Bal Pharma (BALPHARMA.NS) Stock Price
Bal Pharma Price
Over the last 19 years Bal Pharma grew revenue by 8.2% annually, reaching 3.12 B INR. Earnings per share have grown at 6.2% per year over the last 19 years. For Bal Pharma, the net margin of 2.0% is broadly stable versus 2.0% a few years ago. At today's price the dividend yield works out to roughly 1.29%. The payout ratio is around 45% of earnings. The dividend has grown at 1.0% per year over the past 18 years.
Bal Pharma stock price
Bal Pharma business model & stock analysis
Frequently asked questions about Bal Pharma
Converted at the current exchange rate, the Bal Pharma share trades at 0.86 EUR (93.06 INR).
The revenue of Bal Pharma is 3.12 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Bal Pharma is 62.84 M INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bal Pharma is currently 23.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bal Pharma stock.
The price-to-sales ratio (P/S) of Bal Pharma is currently 0.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bal Pharma stock.
The Eulerpool Quality Score for Bal Pharma is 2/10.
The ISIN of Bal Pharma is INE083D01012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Bal Pharma is BALPHARMA.NS. The ticker symbol is used to trade Bal Pharma shares on the stock exchange.
Bal Pharma stock
Bal Pharma Peer Group
Bal Pharma FIGI
All fundamentals and in-depth analysis of Bal Pharma
Our stock analysis for Bal Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bal Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.